Los puntos clave no están disponibles para este artículo en este momento.
ADVERTISEMENT RETURN TO ISSUEPREVHighlights from the ...Highlights from the LiteratureNEXTSome Items of Interest to Process R&D Chemists and EngineersJames A. SchwindemanJames A. SchwindemanLaxai, Daufuskie Island, South Carolina 29915, United StatesMore by James A. Schwindeman, Alex KosanovichAlex KosanovichDow, Texas Operations, 230 Abner Jackson Parkway, ECB/4B137, Lake Jackson, Texas 77566, United StatesMore by Alex Kosanovich, Christopher B. KellyChristopher B. KellyJanssen Research & Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United StatesMore by Christopher B. Kellyhttps://orcid.org/0000-0002-5530-8606, Timothy KwokTimothy KwokVertex Pharmaceuticals, 86-88 Jubilee Avenue, Milton Park, Abingdon OX14 4RW, U.K.More by Timothy Kwokhttps://orcid.org/0000-0003-0634-6654, Elizabeth DaunceyElizabeth DaunceyEarly Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.More by Elizabeth Dauncey, Annabel Q. AnselAnnabel Q. AnselVividion Therapeutics, 5820 Nancy Ridge Drive, San Diego, California 92121, United StatesMore by Annabel Q. Anselhttps://orcid.org/0000-0002-7456-5827, James M. MacDougallJames M. MacDougallCambrex, 1205 11th Street, Charles City, Iowa 50616, United StatesMore by James M. MacDougallhttps://orcid.org/0000-0003-0356-6248, Jimmy LauberteauxJimmy LauberteauxSanofi Winthrop Industrie, 45 chemin Mételine, 04200 Sisteron, FranceMore by Jimmy Lauberteaux, David DayDavid DaySynthetic Medicinal Chemist, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.More by David Day, Sylvain GuizzettiSylvain GuizzettiNovAlix, Building A: Chemistry, Bioparc, Bld. Sébastien Brant, BP 30170, F-67405 Illkirch Cedex, FranceMore by Sylvain Guizzettihttps://orcid.org/0000-0003-4656-2431, and John Knight*John KnightJKonsult Ltd, Meadow View, Cross Keys, Hereford HR1 3NT, U.K.*Email: email protectedMore by John KnightCite this: Org. Process Res. Dev. 2024, 28, 6, 2367–2381Publication Date (Web):June 11, 2024Publication History Received27 May 2024Published online11 June 2024Published inissue 21 June 2024https://pubs.acs.org/doi/10.1021/acs.oprd.4c00238https://doi.org/10.1021/acs.oprd.4c00238editorialACS PublicationsCopyright © Published 2024 by American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views2022Altmetric-Citations-LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (4 MB) Get e-AlertscloseSUBJECTS:Catalysts,Cross coupling reaction,Hydrocarbons,Ligands,Peptides and proteins Get e-Alerts
Schwindeman et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: